American Bio Medica Corp. (ABMC)
| Market Cap | 1.64M |
| Revenue (ttm) | 2.76M |
| Net Income (ttm) | -1.25M |
| Shares Out | 43.80M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,210 |
| Open | 0.0387 |
| Previous Close | 0.0400 |
| Day's Range | 0.0373 - 0.0387 |
| 52-Week Range | 0.0300 - 0.2900 |
| Beta | -2.06 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About ABMC
American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detect...
Financial Performance
In 2020, ABMC's revenue was $4.15 million, an increase of 13.46% compared to the previous year's $3.66 million. Losses were -$796,000, 16.9% more than in 2019.
Financial StatementsNews
ABMC Reports Second Quarter 2021 Results
KINDERHOOK, NY / ACCESSWIRE / August 18, 2021 / American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three and six months ended June 30, 2021. Chief Executive Officer M...
ABMC Reports First Quarter 2021 Results
KINDERHOOK, NY / ACCESSWIRE / May 20, 2021 / American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three months ended March 31, 2021. Chief Executive Officer Melissa A.